UAE Mouth Ulcer Therapeutics Market Analysis

UAE Mouth Ulcer Therapeutics Market Executive Summary

The UAE Mouth Ulcer Therapeutics Market is at around $7.6 Mn in 2023 and is projected to reach $10.6 Mn in 2030, exhibiting a CAGR of 4.9% during the forecast period 2023-2030.

Mouth ulcers, also known as canker sores, are painful and uncomfortable lesions that can appear in various areas of the mouth and gums. Symptoms include one or more painful sores with red edges and a yellow, white, or gray centre, fever, sluggishness, and swollen glands during extreme outbreaks. Causes include stress, anxiety, or hormonal changes, minor mouth injuries, dental appliances or poorly fitting dentures, certain medications, genetic predisposition, nutritional deficiencies, specific medical conditions, allergic reactions to certain foods, toothpastes, or mouthwashes, and vitamin deficiencies. Treatment involves symptomatic relief with topical gels containing anesthetics, antiseptics, and antibiotics, as well as supportive care with multivitamins or vitamin supplements, antipyretics, and antibiotics. Medications include antibiotics, oral painkillers, oral steroids, antiseptics, chlorhexidine gluconate mouthwash, and sucralfate. Home care includes good oral hygiene, avoiding trigger foods, warm saline gargles, ice packs, and a balanced diet. Medical attention is necessary if the ulcers fail to heal within a week or two, are unusual, spreading, or large, or if there is severe pain, fever, or difficulty while chewing, talking, or swallowing.

A study on the prevalence of aphthous ulcers (a type of mouth ulcer) among students at Ras Al Khaimah College of Dental Sciences in the UAE found a lifetime prevalence of 28.2%. The market therefore is driven by significant factors like the increasing prevalence rate mouth ulcers, rising awareness about oral hygiene, and advancements in healthcare, however, factors such as limited accessibility, and competition from substitute treatments limit market growth.

One recent advancement made by a pharmaceutical company in the field of mouth ulcer treatment is the development of a world-first tablet by UK-based Quest Pharm in partnership with Aston University. Other Key players in the market include 3M, Blistex Inc., Colgate-Palmolive Company, Church & Dwight, Inc., GSK among others.

Market Dynamics

Market Growth Drivers

Growing Awareness: The increasing emphasis on oral health education and awareness campaigns has led to a better understanding of mouth ulcers. This has encouraged individuals to seek proper diagnosis and treatment options. Public and private initiatives have played a significant role in raising awareness. Thus, enhancing the market of mouth ulcer.

High Prevalence: Mouth ulcers are a common oral health issue affecting a significant portion of the UAE population. The high prevalence rate approximately around 28.2 attributed to factors such as stress, dietary habits, and underlying medical conditions. This high incidence drives the demand for effective treatment solutions to alleviate symptoms and prevent recurrence.

Advancements in Healthcare: Advancement in healthcare is significantly enhancing the market of oral ulcers, UAE has witnessed significant advancements in its healthcare sector, including in the field of oral health. New treatments, therapies, and pharmaceutical formulations have been introduced to manage mouth ulcers more effectively.

Market Restraints

Competition from Home Remedies: Traditional home remedies and natural treatments for mouth ulcers are widely known and practiced in the UAE. These remedies are often more affordable and easily accessible, posing competition to pharmaceutical treatments.

Limited Accessibility to Pharmaceuticals: Access to pharmaceutical treatments for mouth ulcers may be limited in certain areas of the UAE. Factors like availability in pharmacies, affordability, and healthcare infrastructure can restrict accessibility. This can hinder market growth, especially in remote or underdeveloped regions.

Regulatory Landscape and Reimbursement Scenario

The UAE has a comprehensive, government-funded health service and a rapidly developing private health sector that delivers a high standard of health care to the population. Healthcare is regulated at both the Federal and Emirate level. Public healthcare services are administered by different regulatory authorities in the United Arab Emirates including the Ministry of Health and Prevention, Health Authority-Abu Dhabi (HAAD), the Dubai Health Authority (DHA) and the Emirates Health Authority (EHA). Due to the success of this high standard of care across all stages of the health care system, life expectancy in the UAE is 76.8 years, reaching levels similar to those in Europe and North America. To date, health care in the UAE has been funded mainly by the Government. The UAE in its modernization and path of reform is now evolving this funding to focus on increasingly important public-private partnerships. The UAE’s public policy for health care focuses on developing organizational and legal frameworks based on best practice, and to overhaul and upgrade the private and public sector health service capabilities. In addition, public policy action will set priorities for health services development within the sector.

The UAE cabinet has established the Emirates Drug Corporation (EDC) in September 20231. As a new independent regulator, the EDC will replace the Ministry of Health and Prevention (MOHAP) for the regulation of pharmaceuticals and medical devices. The EDC aims to protect public health and make the UAE a hub for these industries. Its objectives include promoting R&D, enhancing local production capacity, ensuring product availability and safety, and managing manufacturing/marketing processes as per international standards. The EDC will regulate to attract investment while maintaining pharmaceutical security.

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Mouth Ulcers Therapeutics Market:

• Pfizer, Inc.
• Church & Dwight Co. Inc.
• 3M
• Taro Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• BLISTEX, INC.
• GlaxoSmithKline plc.
• ECR Pharmaceuticals
• Sannova
• Reckitt Benckiser
• Sunstar
• Blairex Laboratories
• Sanjin Pharmaceutical
• Joincare Pharmaceutical
• Sinclair Pharma
• Colgate-Palmolive Company